| Autor: |
Trang NTK; Department of Pharmacology and Dental Therapeutics, College of Dentistry, Chosun University, Gwangju 61452, Korea.; Department of Pharmacy, Thai Binh University of Medicine and Pharmacy, Thai Binh City 06000, Vietnam., Yoo H; Department of Pharmacology and Dental Therapeutics, College of Dentistry, Chosun University, Gwangju 61452, Korea. |
| Jazyk: |
angličtina |
| Zdroj: |
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology [Korean J Physiol Pharmacol] 2022 Nov 01; Vol. 26 (6), pp. 439-446. |
| DOI: |
10.4196/kjpp.2022.26.6.439 |
| Abstrakt: |
The antitumoral effects of valdecoxib (Val), an United States Food and Drug Administration-approved anti-inflammatory drug that was withdrawn due to the side effects of increased risk of cardiovascular adverse events, were investigated in hypopharyngeal squamous cell carcinoma cells by performing a cell viability assay, transwell assay, immunofluorescence imaging, and Western blotting. Val markedly inhibited cell viability with an IC50 of 67.3 μM after 48 h of treatment, and also downregulated cell cycle proteins such as Cdks and their regulatory cyclin units. Cell migration and invasion were severely suppressed by inhibiting integrin α4/FAK expression. In addition, Val activated the cell cycle checkpoint CHK2 in response to excessive DNA damage, which led to the activation of caspase-3/9 and induced caspase-dependent apoptosis. Furthermore, the signaling cascades of the PI3K/AKT/mTOR and mitogen-activated protein kinase pathways were significantly inhibited by Val treatment. Taken together, our results indicate that Val can be used for the treatment of hypopharyngeal squamous cell carcinoma. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
